<unk> , sold under the brand names Teysuno and TS-1, is a fixed-dose combination medication used for the treatment of advanced gastric cancer when used in combination with cisplatin, and also for the treatment of head and neck cancer, colorectal cancer, non–small-cell lung, breast, pancreatic, and biliary tract cancers. The most common severe side effects when used in combination with cisplatin include neutropenia (low levels of neutrophils, a type of white blood cell), anaemia (low red blood cell counts) and fatigue (tiredness).<unk>  (Teysuno) was approved for medical use in the European Union in March 2011. It has not been approved by the U.S. Food and Drug Administration (FDA).
Tegafur/gimeracil/oteracil
Trifluridine/tipiracil
Decitabine/cedazuridine
Bicyclomycin
Ethambutol/isoniazid/rifampicin
Trastuzumab/hyaluronidase
Pemetrexed
Isoniazid/pyridoxine/sulfamethoxazole/trimethoprim